2. GPCR/G Protein Neuronal Signaling Apoptosis PI3K/Akt/mTOR
  3. Cholecystokinin Receptor Apoptosis PI3K Akt
  4. Sincalide

Sincalide  (Synonyms: CCK-8; Cholecystokinin octapeptide; CCK-8; SQ19844)

製品番号: HY-P0093 純度: 99.30%
COA 取扱説明書 Technical Support

Sincalide (Cholecystokinin octapeptide, CCK-8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK. Sincalide can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

カスタムペプチド

CAS 番号 : 25126-32-3

容量 価格（税別） 在庫状況 数量
1 mg $110 在庫あり
5 mg $300 在庫あり
10 mg $480 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Other Forms of Sincalide:

Sincalide 関連抗体

Top Publications Citing Use of Products

    Sincalide purchased from MedChemExpress. Usage Cited in: J Gene Med. 2025 Dec;27(12):e70063.  [Abstract]

    Sincalide (Cholecystokinin; CCK) increased the expression of IL-6, TNF-α, and IL-1β in 266-6 cells.

    Sincalide purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2022 Dec 31;12(1):100.

    After transfection with GPX4 siRNA, mouse pancreatic acinar carcinoma 266-6 cells were treated with Sincalide (Cholecystokinin; CCK) (5 μM; 6 h), and lipid reactive oxygen species (ROS) levels and the extent of cell death were determined.

    Sincalide purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25.  [Abstract]

    Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to evaluate the proliferative ability of LUAD cells.

    Sincalide purchased from MedChemExpress. Usage Cited in: Immunogenetics. 2023 Feb;75(1):17-25.  [Abstract]

    Sincalide (CCK-8) (10 μL; 37 ℃; 2 h) was used to illustrate that si-IL4I1 + RO8191 had the ability to reverse the restraining impact of si-IL4I1 on LUAD cell proliferation.

    Sincalide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Aug:116:109001.  [Abstract]

    The OATP superfamily blocker Sincalide (SIN) (20 μM; 2 h) blocked Caba-780 uptake in renal cell carcinoma (RCC) cells.

    Cholecystokinin Receptor アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    CCKAR CCKBR

    PI3K アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

    Akt アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Akt Akt1 Akt2 Akt3

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Sincalide (Cholecystokinin octapeptide, CCK-8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK. Sincalide can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide is a major bioactive segment of CCK that retains most of the biological activities of CCK[1][2][3].

    Cellular Effect
    Cell Line Type Value Description References
    CHO EC50
    0.63 nM
    Compound: CCK8
    Effective concentration for the stimulation of Inositol Phosphate accumulation in CHO cells expressing wild-type Cholecystokinin type B receptor
    Effective concentration for the stimulation of Inositol Phosphate accumulation in CHO cells expressing wild-type Cholecystokinin type B receptor
    		[PMID: 9057851]
    CHO EC50
    0.63 nM
    Compound: CCK-8
    Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain.
    Affinity against Cholecystokinin type B receptor expressed in CHO cells on rat brain.
    		[PMID: 11020275]
    CHO IC50
    1.2 × 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells
    Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells
    		[PMID: 26988801]
    CHO IC50
    1.2 × 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    		[PMID: 27876250]
    CHO IC50
    1.2 x 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells
    Displacement of [125I]CCK-8s from human recombinant CCK-B receptor expressed in CHO cells
    		[PMID: 26988801]
    CHO IC50
    1.2 x 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    Displacement of [125I]CCK-8s from human recombinant CCK2 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    		[PMID: 27876250]
    CHO IC50
    1.3 × 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells
    Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells
    		[PMID: 26988801]
    CHO IC50
    1.3 × 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    		[PMID: 27876250]
    CHO IC50
    1.3 x 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells
    Displacement of [125I]CCK-8s from human recombinant CCK-A receptor expressed in CHO cells
    		[PMID: 26988801]
    CHO IC50
    1.3 x 10-10M
    Compound: CCK-8s
    Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    Displacement of [125I]CCK-8s from human recombinant CCK1 receptor expressed in CHO cells measured after 60 mins by scintillation counting method
    		[PMID: 27876250]
    HEK293 EC50
    27 nM
    Compound: CCK-8, SO3
    Antagonist activity at CCK2 receptor expressed in HEK293 cells assessed as accumulation of [3H]inositol phosphates by PI assay
    Antagonist activity at CCK2 receptor expressed in HEK293 cells assessed as accumulation of [3H]inositol phosphates by PI assay
    		[PMID: 16686530]
    HEK293 EC50
    28 nM
    Compound: CCK-8, SO3
    Antagonist activity at CCK1 receptor expressed in HEK 293 cells assessed as accumulation of [3H]inositol phosphates by PI assay
    Antagonist activity at CCK1 receptor expressed in HEK 293 cells assessed as accumulation of [3H]inositol phosphates by PI assay
    		[PMID: 16686530]
    Jurkat EC50
    0.093 nM
    Compound: sincalide
    Displacement of [125I]CCK-8 from CCK2 receptor in human FGS7 Jurkat cells
    Displacement of [125I]CCK-8 from CCK2 receptor in human FGS7 Jurkat cells
    		[PMID: 16562853]
    Jurkat EC50
    2 nM
    Compound: CCK-8S
    Compound was evaluated for calcium mobilization in Jurkat cells
    Compound was evaluated for calcium mobilization in Jurkat cells
    		[PMID: 10866391]
    体外実験

    Sincalide (Cholecystokinin octapeptide, CCK-8), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. Sincalide also plays a positive role in fighting inflammation, apoptosis and collagen deposition. Sincalide protects H9c2 cardiomyoblasts from Ang II-induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol-3 kinase/protein kinase B (PI3K/Akt) signaling pathway[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Sincalide 関連抗体

    Cell Viability Assay[3]

    Cell Line: H9c2 cells
    Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
    Incubation Time: 24 h
    Result: Attenuated Ang II‐induced toxicity in H9c2 cells

    Apoptosis Analysis[3]

    Cell Line: H9c2 cells
    Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
    Incubation Time: 24 h
    Result: Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.

    Western Blot Analysis[3]

    Cell Line: H9c2 cells
    Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
    Incubation Time: 24 h
    Result: Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.

    RT-PCR[3]

    Cell Line: H9c2 cells
    Concentration: 0.001, 0.01, 0.1, 1, 10, or 100 μmol/L
    Incubation Time: 24 h
    Result: Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.
    体内実験

    Sincalide (Cholecystokinin octapeptide, CCK-8) (i.p.; 50 μg/kg/d; for 4 weeks) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: MI rat model[4]
    Dosage: 50 μg/kg
    Administration: i.p.; 50 μg/kg/d; for 4 weeks
    Result: Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.
    分子量

    1143.27

    分子式

    C49H62N10O16S3
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    Sequence

    Asp-{SO3H-Tyr}-Met-Gly-Trp-Met-Asp-Phe-NH2
    Sequence Shortening

    D-{SO3H-Tyr}-MGWMDF-NH2
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    polypeptide, sealed storage, away from moisture and light, under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (polypeptide, sealed storage, away from moisture and light, under nitrogen)
    溶剤 & 溶解度
    体外: 

    H2O : 50 mg/mL (43.73 mM; ultrasonic and adjust pH to 11 with NH3·H2O)

    DMF : 50 mg/mL (43.73 mM; Need ultrasonic)

    DMSO : 25 mg/mL (21.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 0.8747 mL 4.3734 mL 8.7468 mL
    5 mM 0.1749 mL 0.8747 mL 1.7494 mL
    10 mM 0.0875 mL 0.4373 mL 0.8747 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (2.19 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    純度とドキュメンテーション
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O / DMF 1 mM 0.8747 mL 4.3734 mL 8.7468 mL 21.8671 mL
    5 mM 0.1749 mL 0.8747 mL 1.7494 mL 4.3734 mL
    10 mM 0.0875 mL 0.4373 mL 0.8747 mL 2.1867 mL
    15 mM 0.0583 mL 0.2916 mL 0.5831 mL 1.4578 mL
    20 mM 0.0437 mL 0.2187 mL 0.4373 mL 1.0934 mL
    H2O / DMF 25 mM 0.0350 mL 0.1749 mL 0.3499 mL 0.8747 mL
    30 mM 0.0292 mL 0.1458 mL 0.2916 mL 0.7289 mL
    40 mM 0.0219 mL 0.1093 mL 0.2187 mL 0.5467 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Sincalide Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Sincalide25126-32-3Cholecystokinin octapeptide CCK-8 SQ19844CCK8CCK 8CCK-8SQ19844SQ 19844SQ-19844Cholecystokinin ReceptorApoptosisPI3KAktCCK ReceptorPhosphoinositide 3-kinasePKBProtein kinase BCK‐8CCKpostevacuation cholecystographycardiovascular hormoneinflammationapoptosisPI3K/AktInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Sincalide
    製品番号:
    HY-P0093
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.